Mangoceuticals, Inc. (NASDAQ: MGRX) reported that its newly launched injectable testosterone replacement therapy (TRT) program, which began mid‑December 2025, has achieved a 336 % month‑over‑month sales increase and a 54 % reduction in customer acquisition costs. The $99‑per‑month subscription bundles physician visits, medical consultations, lab work and the prescribed medication, all delivered through the company’s telehealth platform.
The early performance data represent the first substantive performance metrics for the TRT offering and signal that Mangoceuticals is successfully expanding beyond its original men’s wellness focus. Management highlighted the rapid sales acceleration as evidence of strong demand for convenient, discreet hormone‑health solutions and underscored the program’s role as a key growth driver moving forward.
While the TRT program’s results are encouraging, the company’s broader financial picture remains challenging. Recent filings show declining revenues and increasing net losses, and the company has faced a Nasdaq notice regarding its minimum bid price. Share dilution from recent equity offerings also adds pressure. Management acknowledged these headwinds, noting that the company is working to strengthen its operational and financial foundation.
Management emphasized that the TRT program’s success is a strategic pivot: “We are encouraged by this initial customer demand and sales acceleration in our injectable TRT product, which we believe demonstrates the value of our innovative approach to men’s hormone health and underscores TRT as our key strategic focus.” The company plans to expand both injectable and oral TRT offerings, positioning itself as a comprehensive platform for men’s health.
Investors reacted strongly to the announcement, with the stock experiencing a significant rally in pre‑market trading. The market reaction was driven primarily by the 336 % month‑over‑month sales growth and the 54 % reduction in customer acquisition costs, which validated the $99 subscription model and reinforced confidence in the company’s new growth strategy.
The early results suggest that Mangoceuticals has found a successful product‑market fit with its telehealth‑delivered TRT program. However, the company must continue to address its overall financial challenges to sustain long‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.